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Brachytherapy 13 (2014) S1eS14Listing of Plenary, Oral and Poster Presentations of the 35th Annual
Meeting of the American Brachytherapy SocietyPLENARY SESSION
Friday, April 4, 2014
11:15 AM - 12:15 PM
PL01 Presentation Time: 11:15 AM
Interstitial Multi-Catheter Brachytherapy for Breast Cancer: A
Multi-Institutional Study
Mitchell Kamrava, MD. Radiation Oncology, University of
California Los Angeles, Los Angeles, CA.PL02 Presentation Time: 11:30 AM
A Deformable Image Registration Method for Dose Accumulation
between HDR CT Images
Xin Zhen, PhD. Biomedical Engineering, Southern Medical
University, Guangzhou, China.PL03 Presentation Time: 11:45 AM
Trends in the Utilization of Brachytherapy Boost in Vaginal Cancer
in the United States
Man (Karen) Xu, BS. Radiation Oncology, University of
Pittsburgh Cancer Institute, Pittsburgh, PA.PL04 Presentation Time: 12:00 PM
Aging Effect and Long-Term Erectile Function following I-125
Permanent Prostate Brachytherapy
Mira Keyes, MD, FRCPC. Radiation Oncology, BC Cancer
Agency, Vancouver, BC, Canada.BREAST ORAL
Thursday, April 3, 2014
10:45 AM - 11:45 AM
OR01 Presentation Time: 10:45 AM
The Evolution of Accelerated Partial Breast Irradiation:
Comparative Analysis of Clinical Outcomes with Interstitial vs
Balloon-Based Treatment
Peter Y. Chen, MD, FACR. Radiation Oncology, Beaumont
Health System, Royal Oak, MI.OR02 Presentation Time: 10:54 AM
The Cost of Convenience: A Cost-Comparison Analysis Comparing
External Beam Radiation Therapy, High-Dose-Rate Brachytherapy
and Permanent Seed Implants for Early Stage Breast Cancer1538-4721  2014 American Brachytherapy Society. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.brachy.2014.02.442Merrylee A. McGuffin, MSc, BSc, MRT(T). Odette Cancer
Centre, Sunnybrook Health Sciences Centre, Toronto, ON,
Canada.
OR03 Presentation Time: 11:03 AM
A Novel Approach for Real-Time, Personalized Breast HDR
Brachytherapy Treatment Using 3D Printing Technology
Eric Poulin, MSc. Radio-Oncologie, Centre Hospitalier
Universitaire de Quebec, Quebec, QC, Canada.
OR04 Presentation Time: 11:12 AM
Recurrence Rates by Age Stratification for Accelerated Partial
Breast Irradiation Using Strut-Based Brachytherapy in Ductal
Carcinoma In Situ Patients: A Report on 284 Patients
John P. Einck, MD. Radiation Medicine and Applied Sciences,
University of California, San Diego, La Jolla, CA.
OR05 Presentation Time: 11:21 AM
Update on a Multi-Institutional Study of Noninvasive Breast
Brachytherapy for Tumor Bed Boost: Cosmesis and Tumor Control
Jessica M. Schuster, MD. Radiation Oncology, Virginia
Commonwealth University, Richmond, VA.OR06 Presentation Time: 11:30 AM
Dosimetric Comparison of Multi-Channel Balloon Catheter HDR
Brachytherapy to 50kv X-Rays as Techniques for Intraoperative
Radiation Therapy
Bruce Libby, PhD. Radiation Oncology, University of Virginia,
Charlottesville, VA.MISCELLANEOUS ORAL
Thursday, April 3, 2014
2:00 PM - 3:00 PM
OR07 Presentation Time: 2:00 PM
Local Control Outcomes Using the 32P Intraoperative
Brachytherapy Plaque in the Management of Malignant Lesions of
the Spine Involving the Dura
Michael R. Folkert, MD, PhD. Radiation Oncology, Memorial
Sloan-Kettering Cancer Center, New York, NY.OR08 Presentation Time: 2:09 PM
Yttrium-90 Microsphere Brachytherapy for Liver Metastases from
Uveal MelanomaOpen access under CC BY-NC-ND license.
S2 Listing of Presentations / Brachytherapy 13 (2014) S1eS14Harriet B. Eldredge-Hindy, MD. Radiation Oncology, Thomas
Jefferson University, Philadelphia, PA.OR09 Presentation Time: 2:18 PM
The Role of Brachytherapy in Organ Preservation for Penile
Cancer: A Meta-Analysis and Systematic Review of the Literature
Shaakir Hasan, BS. College of Osteopathic Medicine, Nova
Southeastern University, Fort Lauderdale, FL.OR10 Presentation Time: 2:27 PM
A Robust Workflow of a Multidisciplinary Team-Involved Radiation
Therapy Procedure – A Case in Yttrium-90 Microsphere
Radioembolization
Bin Cai, PhD. Radiation Oncology, Washington University in St.
Louis, St. Louis, MO.OR11 Presentation Time: 2:36 PM
The Investigation of 125I Seed Implantation as a Salvage Modality
for Unresectable Pancreatic Carcinoma
Hao Wang, Doctor. Radiation Oncology, Peking University Third
Hospital, Beijing, China.OR12 Presentation Time: 2:45 PM
The American Brachytherapy Society (ABS) Consensus Guidelines
for Plaque Brachytherapy of Uveal Melanoma and Retinoblastoma
Paul T. Finger, FACS. Ocular Tumor, Orbital Disease and
Ophthalmic Radiation Therapy, New York Eye Cancer Center,
New York, NY.OR13 Presentation Time: 2:54 PM
Numerical Comparison between High-Dose-Rate Brachytherapy and
Electron Beam Therapy in Cutaneous Oncology
Ivan Buzurovic, PhD. Radiation Oncology, Dana-Farber/
Brigham and Women’s Cancer Center, Harvard Medical School,
Boston, MA.
PHYSICS ORAL
Thursday, April 3, 2014
3:30 PM - 5:00 PM
OR14 Presentation Time: 3:30 PM
Generalized Equivalent Uniform Dose To Evaluate Overall OAR
Doses of EBRTand 3D Image-Guided Adaptive HDR Brachytherapy
for Cervical Cancer
Yusung Kim, PhD. Radiation Oncology, University of Iowa, Iowa
City, IA.OR15 Presentation Time: 3:39 PM
Dosimetric Characteristics of a New Unit for Electronic Skin
Brachytherapy
Teresa Garcia-Martinez, Medical Physicist. Radiotherapy
Oncology, Hospital Universitario y Politecnico La Fe, Valencia,
Spain.OR16 Presentation Time: 3:48 PM
Evaluation of Treatment Plan Robustness to Changes in Treatment
Geometry for Strut Adjusted Volume Implant Breast BrachytherapyNels Knutson, MS. Washington University School of Medicine,
St. Louis, MO.
OR17 Presentation Time: 3:57 PM
Towards Accurate OAR Dose Accumulation in Cervix
Brachytherapy: Applying a Non-Rigid Point Matching Method for
Bladder Deformation
Xin Zhen, PhD. Biomedical Engineering, Southern Medical
University, Guangzhou, China.
OR18 Presentation Time: 4:06 PM
Pd-103 Strings: A New Approach to Brachytherapy Source Design
Mark J. Rivard, PhD. Radiation Oncology, Tufts University
School of Medicine, Boston, MA.
OR19 Presentation Time: 4:15 PM
A Novel Algorithm Accounting for Inter-Seed Attenuation Effect in
Brachytherapy Treatment Planning Systems by Monte Carlo and
Artificial Neural Networks
Habib Safigholi, PhD. Ray Medical and Biomedical
Engineering, Science and Research Branch, Islamic Azad
University, Fars, Persepolis - Shiraz, Iran, Islamic Republic of.
OR20 Presentation Time: 4:24 PM
Monte Carlo Simulation of HDR Ir-192 Brachytherapy Cancer
Treatments
Gabriel P. Fonseca, MSc1,2. 1Centro de Engenharia Nuclear,
Instituto de Pesquisas Energeticas e Nucleares, S~ao Paulo,
Brazil, 2Radiation Oncology, Maastro Clinic, Maastricht,
Netherlands.
OR21 Presentation Time: 4:33 PM
Dynamic Modulated Brachytherapy for Cervical Cancer
Dae Yup Han, MSc. Radiation Medicine and Applied Sciences,
University of California, San Diego, San Diego, CA.
OR22 Presentation Time: 4:42 PM
Measurement and Comparison of Surface Dose Outside Treatment
Area for Different Radiation Treatment Modalities in Breast Cancer
Patients Using Thermoluminescence Dosimeters
Suraj Prasad Khanal, Master in Medical Physics. Physics,
Florida Atlantic University, Boca Raton, FL.
GYNECOLOGY ORAL
Friday, April 4, 2014
8:00 AM - 9:30 AM
OR23 Presentation Time: 8:00 AM
3D Conformal Brachytherapy for Inoperable Endometrial
Carcinoma: Discrepancies Between CTV EQD2 Values and Local
Control
Beant S. Gill, MD. Radiation Oncology, University of Pittsburgh
Cancer Institute, Pittsburgh, PA.OR24 Presentation Time: 8:09 AM
MRI Immediately before Cervical Cancer Brachytherapy and
Impact on Dosimetric Values Compared to CT or MRI During
Brachytherapy
S3Listing of Presentations / Brachytherapy 13 (2014) S1eS14Nicole Cimbak, BS1,2. 1Brigham and Women’s Hospital, Boston,
MA. 2Dana-Farber Cancer Institute, Boston, MA.OR25 Presentation Time: 8:18 AM
Image-Guided Brachtherapy for Locally Advanced Cervical Cancer:
Can Deformable Image Registration Replace MRI Simulation?
Lauren Tait, MD. Radiation Oncology, University of California,
Davis, Sacramento, CA.OR26 Presentation Time: 8:27 AM
Three-Dimensional Dosimetric Evaluation of Urethral Toxicity with
Interstitial Needle High-Dose-Rate Brachytherapy for Gynecologic
Malignancy
Jonathan W. Thompson, MD. Radiation Oncology, University of
Alabama at Birmingham, Birmingham, AL.OR27 Presentation Time: 8:36 AM
Dose Reduction to Rectum and Bladder Using the Fletcher CT/MR
Shielded Applicator for Cervical Cancer Brachytherapy
Katherine O. Castle, MD. Radiation Oncology, MD Anderson,
Houston, TX.OR28 Presentation Time: 8:45 AM
Long-Term Outcomes for Primary Vaginal Cancer: The CET/UCLA
Experience
Robyn Banerjee, MD. Oncology, University of Calgary, Calgary,
AB, Canada.OR29 Presentation Time: 8:54 AM
Extended Clinical Outcomes of 3D High-Dose-Rate Intracavitary
Brachytherapy with MRI-Based Planning for Treatment of Cervical
Cancer
Beant S. Gill, MD. Radiation Oncology, University of Pittsburgh
Cancer Institute, Pittsburgh, PA.OR30 Presentation Time: 9:03 AM
Patterns of Care and Outcomes for Women with Stage II
Endometrial Carcinoma Treated with Vaginal Brachytherapy: A
Seer Database Analysis
Kara L. Leonard, MD. Radiation Oncology, Rhode Island
Hospital, Brown Alpert Medical School, Providence, RI.OR31 Presentation Time: 9:12 AM
The Impact of Smoking on Recurrence and Survival in Locally
Advanced Cervical Cancer Treated with Radiation and
Brachytherapy
Jihoon Lim, BA. School of Medicine, University of California,
Davis, Sacramento, CA.OR32 Presentation Time: 9:21 AM
Do Women Undergoing Image-Guided Brachytherapy Need an MR
on Every Fraction?
Junzo Chino, MD. Radiation Oncology, Duke Cancer Institute,
Durham, NC.PROSTATE ORAL I
Friday, April 4, 2014
8:00 AM - 9:30 AM
OR33 Presentation Time: 8:00 AM
PSA Outcomes in a Single Institution, Prospective Randomized
131Cs/125I Permanent Prostate Brachytherapy Trial
Brian J. Moran, MD. Prostate Cancer Foundation of Chicago,
Westmont, IL.OR34 Presentation Time: 8:09 AM
Continued Benefit to Local Control Even in Very High-Risk Prostate
Cancer
Daniel A. Hamstra, MD, PhD. The University of Michigan, Ann
Arbor, MI.OR35 Presentation Time: 8:18 AM
Favorable Long-Term (10-15 Year) Results with High-Dose-Rate
Brachytherapy for Prostate Cancer
Henrik Hauswald, MD. Radiation Oncology, University of
California at Los Angeles, Los Angeles, CA.OR36 Presentation Time: 8:27 AM
Utilization of Brachytherapy for the Treatment of Localized Prostate
Cancer in the National Cancer Database
Jeffrey M. Martin, MD, MS. Radiation Oncology, Fox Chase
Cancer Center, Philadelphia, PA.OR37 Presentation Time: 8:36 AM
National and Regional Patterns of Prostate Brachytherapy
Utilization in Relation to The New York Times Brachytherapy Article
Usama Mahmood, MD. Radiation Oncology, MD Anderson,
Houston, TX, USA.OR38 Presentation Time: 8:45 AM
Single 15 Gy High-Dose-Rate Brachytherapy Boost for Treatment of
Prostate Cancer: Long-Term Results of Changes in Health-related
Quality of Life and Toxicity
Negin Shahid, MD, MSc. Radiation Oncology, University of
Toronto, Toronto, ON, Canada.OR39 Presentation Time: 8:54 AM
10-Year Outcomes of Prostate Brachytherapy in Japan
Yasuto Yagi, Dr, Urology, Tokyo Medical Center, Tokyo, Japan.OR40 Presentation Time: 9:03 AM
Six-Year Biochemical Outcome in Patients Treated with Cs-131
Brachytherapy as Monotherapy for Prostate Cancer
Malolan S. Rajagopalan, MD. Radiation Oncology, University
of Pittsburgh Cancer Institute, Pittsburgh, PA.OR41 Presentation Time: 9:12 AM
Regional Dosimetric Analysis of LDR Prostate Brachytherapy
Patients with Confirmed Local Failure: A Case-Control Study
Maryam Afsari Golshan, MSc. Medical Physics, BC Cancer
Agency, Vancouver, BC, Canada.
S4 Listing of Presentations / Brachytherapy 13 (2014) S1eS14OR42 Presentation Time: 9:21 AM
Salvage MRI-Guided and Tumor-Targeted HDR Prostate
Brachytherapy after External Beam Radiotherapy
Trish Pulvirenti, MBBS, FRANZCR. Radiation Oncology,
University of Toronto, Princess Margaret Cancer Centre,
Toronto, ON, Canada.OR43 Presentation Time: 9:30 AM
HDR Brachytherapy for Treatment of Local Recurrent Prostate
Cancer
Lyczek Jaroslaw, MD, PhD. Brachytherapy, Podkarpacki Cancer
Center, Brzozow, Poland.PROSTATE ORAL II
Saturday, April 5, 2014
9:30 AM - 10:30 AM
OR44 Presentation Time: 9:30 AM
Late Urinary Side Effects after LDR Prostate Brachytherapy: The
British Columbia Cancer Agency Experience
Mira Keyes, MD FRCPC. Radiation Oncology, BC Cancer
Agency, Vancouver, BC, Canada.OR45 Presentation Time: 9:39 AM
Rectal Ulcers and Recto-prostatic Fistulas Following I-125 LDR
Prostate Brachytherapy
Nelson Leong, BSc, MD, FRCPC. Radiation Oncology, BC
Cancer Agency - Vancouver Island Centre, Victoria, BC,
Canada.OR46 Presentation Time: 9:48
Oncologic and Toxicity Outcomes after Prostate Brachytherapy for
HIV-Positive Patients
John Nicholas Lukens, MD. Radiation Oncology, Beth Israel
Medical Center, New York, NY.OR47 Presentation Time: 9:57 AM
Electromagnetic Catheter Digitization in Prostate High-Dose-Rate
Brachytherapy Treatment Planning
Alexandru M. Nicolae, BSc. Medical Physics, Sunnybrook
Health Sciences Centre, Toronto, ON, Canada.OR48 Presentation Time: 10:06 AM
A Prospective Study of Registered Ultrasound and
Fluoroscopy for Intraoperative Dose Calculation: Improved
Accuracy Compared To Current Ultrasound-based Intraoperative
Dosimetry
Omar Y. Mian, MD, PhD. Radiation Oncology and
Molecular Radiation Sciences, Johns Hopkins Hospital,
Baltimore, MD.OR49 Presentation Time: 10:15 AM
Anatomic Variability of the Neurovascular Elements Defined by
MRIAdam Liss, MD. Radiation Oncology, University of Michigan,
Ann Arbor, MI.OR50 Presentation Time: 10:24 AM
Real-time Electromagnetic Seed Drop Detection Validation
for Low-Dose-Rate Brachytherapy: An Approach Exploiting
RF/Electromagnetic Technologies
Emmanuel Racine, PhD. Radio-Oncology, Centre de Recherche
du CHU de Quebec, Quebec, QC, Canada.POSTER DISCUSSION: MISCELLANEOUS
Thursday, April 3, 2014
10:45 AM - 11:45 AM
PD01
CT-Guided Radioactive Seed Implantation for Locally Recurrent
Rectal Cancer
Hao Wang, Master. Radiation Oncology, Peking University Third
Hospital, Beijing, China.PD02
A 3-Year Result of Permanent Implantation of Iodine-125 Seeds as a
Salvage Therapy for Recurrent Head and Neck Carcinoma after
External Beam Radiotherapy and/or Surgery
Yuliang Jiang, MD. Radiation Oncology, Peking University
Third Hospital, Beijing, China.PD03
Percutaneous Computed Tomography-Guided Permanent 125I
Implantation for Treating Recurrent Head and Neck Cancer
Suqing Tian, MD, PhD. Cancer Center, Peking University Third
Hospital, Beijing, China.PD04
An HDR Method for the Treatment of Full Face Cutaneous T-cell
Lymphoma
Desmond A. O’Farrell, MSc. Dana Farber/Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA.PD05
The Biological Effectiveness of 125I Radioactive Seeds Continuous
Low-Dose-Rate Radiation on KYSE150 Esophageal Cancer Cells
Lifa Du, Master. Radiation Oncology, Peking University Third
Hospital, Beijing, China.PD06
A Non-Invasive Brachytherapy Technique for Carcinoma of the
Penis
Benjamin D. Weinberg, MD. Radiation Oncology, Wayne State
University, Detroit, MI.PD07
Skin Lesion Treatment Using High-Dose-Rate Brachytherapy with
HAM Applicator: EQD2Gy Comparison with Electron Beam
Radiotherapy
S5Listing of Presentations / Brachytherapy 13 (2014) S1eS14Y. Jessica Huang, PhD. Radiation Oncology, University of Utah,
Salt Lake City, UT.PD08
Current State of Brachytherapy Teaching in Canada: A National
Survey of Radiation Oncologists, Residents and Fellows
Marc Gaudet, MD, MSc. Radiation Oncology, CSSS de
Gatineau, Gatineau, QC, Canada.PD09
High-Dose-Rate Brachytherapy Boost in Adjunct to Concurrent
Preoperative Chemotherapy and Pelvic Radiotherapy for Locally
Advanced Rectal Cancer: Single Institution Experience
Mohamed E. El Sayed, PhD1,2. 1Oncology, Radiation Oncology
Section, King Faisal Specialist Hospital and Research Center,
Jeddah, Saudi Arabia, 2Radiation Oncology and Nuclear
Medicine, National Cancer Institute-Cairo University, Cairo,
Egypt.PD10
Mid-Level Providers in Radiation Oncology and Their Role in
Brachytherapy
Amy Hacker-Prietz, MS, PA-C. Radiation Oncology, Johns
Hopkins University, Baltimore, MD.PD11
Electronic Brachytherapy for Non-Melanomatous Skin Cancer:
Report of First 565 Lesions
Stephen Doggett, MD. Transdermal Radiation Oncology
Associates, Tustin, CA.PD12
CT-Guided 125I Seed Implantation on Treatment of Recurrent Soft
Tissue Sarcoma after Multimodal Treatment
Lei Lin, PhD. Radiation Oncology, Peking University 3rd
Hospital, Beijing, China.
POSTER DISCUSSION: PHYSICS
Friday, April 4, 2014
8:00 AM - 9:30 AM
PD13
Evaluation of a New MRI Compatible Brachytherapy Ano-rectal
Applicator
Gilad N. Cohen, MS. Medical Physics, Memorial Sloan
Kettering Cancer Center, New York, NY.PD14
Phenomenological Method for Heterogeneity Corrected Eye Plaque
Dosimetry Using Line Source TG-43 Functions in Brachyvision TPS.
The Mayo Technique?
Christopher L. Deufel, PhD. Radiation Oncology, Mayo Clinic,
Rochester, MN.PD15
Comparative Dosimetry of Two Electronic Brachytherapy Systems:
Xoft Axxent Electronic Brachytherapy System (50 Kvp) and Esteya(Elekta) Electronic Brachytherapy System (69.5 Kvp) for Skin
Application
Sujatha Pai, M.S. DABMP. Good Samaritan Hospital, Radion
Global, Inc, Cupertino, CA.PD16
Establishing Universal Test Cases for Benchmarking Model-Based
Dose Calculations beyond TG-43
Facundo Ballester, PhD. Atomic, Molecular and Nuclear
Physics, University of Valencia, Burjassot, Spain.PD17
Dosimetric Comparison Between a Commercial Collapsed Cone
Algorithm and the TG-43 Method for Accelerated Partial Breast
Irradiation Brachytherapy
Tao Han, PhD. The University of Texas MD Anderson Cancer
Center, Houston, TX.PD18
EPID-based Quality Assurance Technique for HDR Ring and
Tandem Source Dwell Positions with the Nucletron Flexitron
Afterloader
Cindy Tam, MSc. Medical Physics, Sunnybrook Odette Cancer
Centre, Toronto, ON, Canada.PD19
Investigation of the GliaSite Balloon Brachytherapy System Using
I-125 and Cs-131 Solutions
Mark J. Rivard, PhD. Radiation Oncology, Tufts University
School of Medicine, Boston, MA.PD20
Dynamic Modulated Brachytherapy for Accelerated Partial Breast
Irradiation
Matthew J. Webster, MS. Radiation Medicine and Applied
Sciences, UCSD, San Diego, CA.PD21
Validation of the Oncentrabrachy Collapsed Cone Convolution
Algorithm Using Real Patient Heterogeneous Geometries
Yunzhi Ma, PhD. Radio-Oncologie, Le Centre Hospitalier
Universitaire de Quebec (CHUQ), Quebec City, QC, Canada.PD22
Correction Required for Formula Used to Determine
‘‘Correspondence Factor’’ of the Valencia Skin Applicator
Sook Kien Ng, PhD. Johns Hopkins University, Baltimore, MD.PD23
MOSkin Detectors for On Line Dosimetry in HDR Ultrasound-
Guided Prostate Brachytherapy: Rectal Wall (In Vivo) and Urethra
(In Phantom) Measurements
Mauro Carrara, PhD. Diagnostic Imaging and Radiation
Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori,
Milan, Italy.
S6 Listing of Presentations / Brachytherapy 13 (2014) S1eS14PD24
A Dosimetric Update of the Model S700 Xoft Axxent 50 kV
Electronic Brachytherapy Source Including a Cloverleaf-Shaped
Insert
Jessica R. Hiatt, MS. Radiation Oncology, Rhode Island
Hospital, Providence, RI.PD25
CT and Radio Film Evaluation of PC-ISO and Its Application to
Customized GYN Brachytherapy
Katherine Mellis, BS. (expected 2014). Bioengineering,
University of California, Berkeley, Berkeley, CA.PD26
Pre-treatment Verification of Catheter Positioning for HDR Prostate
Brachytherapy
Harald Keller, PhD1,2. 1Radiation Medicine Program, Princess
Margaret Cancer Centre, Toronto, ON, Canada, 2Radiation
Oncology, University of Toronto, Toronto, ON, Canada.PD27
Dosimetric Properties of a New D-Cone Applicator for Breast
Brachytherapy
Yun Yang, PhD. Radiation Oncology, Tufts University School of
Medicine, Boston, MA.POSTER DISCUSSION: GYNECOLOGY I
Friday, April 4, 2014
2:00 PM - 3:30 PM
PD28
Optimizing Packing Contrast for MRI-Based Intracavitary
Brachytherapy Treatment Planning
Cameron W. Swanick, MD. Radiation Oncology, MD Anderson
Cancer Center, Houston, TX.PD29
Dosimetric Benefit of Intracavity and Interstitial Combination
Brachytherapy for Locally Advanced Cervical Cancer
Kana Takahashi, MD. National Cancer Center Hospital, Tokyo,
Japan.PD30
Operable IB and IIB Cervical Cancer: A Retrospective Study
Comparing Two Treatment Schedules: Preoperative HDR
Brachytherapy and Postoperative Adjuvant Radiotherapy
Sylwia Kellas-Sleczka, MD, PhD. Brachytherapy, Maria
Sklodowska-Curie Memorial Cancer Center and Institute of
Oncology Gliwice Branch, Gliwice, Poland.PD31
A New Mixed Intracavitary and Interstitial Perineal Template
Compatible With MRI ABS-ESTRO Recommendations
Silvia Rodriguez Villalba, Radiation Oncologist/Chair Of
Brachytherapy. Radiation Oncology, Hospital Clinica Benidorm,
Benidorm, Spain.PD32
Intracavitary Brachytherapy with Mini-Ovoid for Cervical Cancer:
CT-Based Residual Tumor Dimensions vs Local Control and Disease
Free Survival
Javier J. Lopez Araujo, MD. Radiation Oncology, University of
Alabama at Birmingham, Birmingham, AL.PD33
Dosimetric Comparison of Vaginal Balloon Packing and
Conventional Gauze Packing for High-dose-rate Intracavitary
Brachytherapy for Cervical Carcinoma
Matthew D. Hall, MD, MBA. Radiation Oncology, City of Hope
National Medical Center, Duarte, CA.PD34
Withdrawn
PD35
Current State of External Beam Radiation Therapy and
Brachytherapy for Cervix Cancer in Ontario
Iwa Kong, MD, MSc, FRCPC. Radiation Oncology, Juravinski
Cancer Centre, Hamilton, ON, Canada.PD36
Dosimetric Comparison of Image-Guided Brachytherapy and
Stereotactic Body Radiotherapy for Lymph Node Boost Irradiation
in Gynecologic Malignancies
Sang-June Park, PhD. Radiation Oncology, University of
California Los Angeles, Los Angeles, CA.PD37
Can Inverse Planning Further Increase the Dose Coverage to Local
Advanced Cervical Cancer Treated with Intracavitary Combined
Interstitial Brachytherapy?
Hsiang-Chi Kuo, PhD. Montefiore Medical Center, Bronx, NY.PD38
Dosimetric Study of a New Utrecht-Style Applicator for Cervical
Brachytherapy
Ryan C.M. Best, PhD. Radiation Oncology, University of
Virginia Health System, Charlottesville, VA.PD39
Dose to Pelvic Lymph Nodes with Image-Guided Brachytherapy in
Patients with Locally Advanced Cervical Cancer
Sommer Rae Wild Nurkic, MPH. University of North Dakota
School of Medicine and Health Sciences, Fargo, ND.PD40
3T MR Image-Guided Cervix Brachytherapy with Novel
Immobilization - Initial Experience
Mark J. Stevens, MD FRANZCR. Radiation Oncology, Royal
North Shore Hospital, Sydney, Australia.
S7Listing of Presentations / Brachytherapy 13 (2014) S1eS14PD41
A Ready Reference for Estimating Dose to Pelvic Node Metastases
from High-Dose-Rate Brachytherapy in Cervical Cancer
Matthew R. McKeever, BS. University of Texas Southwestern
Medical School, Dallas, TX.PD42
Impact of Various Treatment Modalities for Carcinoma Cervix on
Sexual Function Assessed Using the LENT SOMA Scales
Abhishek Shankar, MD. Radiation Oncology, All India Institute
of Medical Sciences, New Delhi, India.POSTER DISCUSSION: PROSTATE
Friday, April 4, 2014
2:00 PM - 3:30 PM
PD43
A Comparative Study of Quality of Life in Patients with Localized
Prostate Cancer Treated in a Single Institution: Stereotactic
Radiotherapy or External Beam D High-Dose-Rate Brachytherapy
Boost
Joelle Helou, MD. Radiation Oncology, Sunnybrook Odette
Cancer Centre, Toronto, ON, Canada.PD44
Mapping Prostate Biopsy Results following Continuous PSA Rises in
Patients Treated with Iodine-125 Prostate Brachytherapy
Atsunori Yorozu, MD. Radiation Oncology, Tokyo Medical
Center, NHO, Meguro-ku, Tokyo, Japan.PD45
HDR Brachytherapy Boost for Prostate: Dosimetry and Toxicity
Comparison Study Based on Prostate Volumes
Marie-Claude Lavallee, PhD. Radiation Oncology, CHU de
Quebec, Quebec, QC, Canada.PD46
Assessing Prostate HDR Brachytherapy Plan Quality: Dose Versus
Volume Metrics
Sarah Geneser, PhD. Radiation Oncology, University of
California San Francisco, San Francisco, CA.PD47
Influence of Body Mass Index and Periprostatic Fat on Rectal
Dosimetry in Permanent Seed Prostate Brachytherhapy
David Tiberi, BSc. Radiation Oncology, University of Montreal,
Montreal, QC, Canada.PD48
A Novel Ultrasound-CT Deformable Registration Process Improves
Physician Contouring during CT-Based HDR Brachytherapy for
Prostate Cancer
Xiaofeng Yang, PhD. Radiation Oncology, Emory University,
Atlanta, GA.PD49
Withdrawn
PD50
Targeted Biopsies Provide a More Accurate Representation of
Gleason Score and Prostate Cancer Tumor Volume Compared with
Standard Systematic Biopsies
Mitchell Kamrava, MD. Radiation Oncology, University of
California Los Angeles, Los Angeles, CA.
PD51
Peripheral Zone Prostate Cancer Lesions on Diffusion Weighted
Imaging MRI Show Different Correlations with Gleason Score,
NCCN Risk and Tumor Size than Central Lesions
Nicolas T. Kummer, MD, PhD. Radiation Oncology, University
of California Los Angeles, Los Angeles, CA.
PD52
Rectal Function following 125I Seeds Brachytherapy - Dosimetry
and Sector Analysis Comparison with Toxicity
Anysja Zuchora, MSc. Medical Physics, University Hospital
Galway, Galway, Ireland.
PD53
Validation of the Prostate Tumorlet Model Based on Multi-
Institution Clinical Data
Dorin Todor, PhD. Radiation Oncology, Virginia Commonwealth
University, Richmond, VA.
PD54
Dosimetric Comparison of High-Dose-Rate Brachytherapy, Helical
Tomotherapy and Linac Based Intensity Modulated Radiaiton
Therapy for Definitive Localized Prostate Cancer Treatment
Thomas B. Skidmore, MD. Radiation Oncology, Gammawest
Cancer Services, Salt Lake City, UT.
PD55
Impact of Technology and Learning Curve on Migration and Seed
Loss in Permanent Prostate Implants
Sylviane Aubin, MSc. Radiation Oncology, CHU de Quebec,
Quebec, QC, Canada.
PD56
Preliminary Results of a Pilot Study of Focal Salvage High-Dose-
Rate Prostate Brachytherapy in Patients with Local Recurrence
after Definitive External Beam Radiotherapy
Hans T. Chung, MD, FRCPC. Radiation Oncology, Sunnybrook
Odette Cancer Center, Toronto, ON, Canada.
PD57
PSA Bounce after Standard Fractionation or Hypofractionated
External Beam Radiotherapy and Brachytherapy: An Investigation
of Its Etiology and Comparison of Its Occurrence
Alexandra Waters, MD. Radiation Oncology, CHUM, Montreal,
QC, Canada.PD58
Phase I Study of Targeting Dominant Intraprostatic Lesion Using
Functional Imaging with MR Spectroscopy and High-Dose-Rate
Brachytherapy
S8 Listing of Presentations / Brachytherapy 13 (2014) S1eS14Steve Braunstein, MD, PhD. University of California, San
Francisco, San Francisco, CA.POSTER DISCUSSION: GYNECOLOGY II
Friday, April 4, 2014
4:00 PM - 5:00 PM
PD59
A Novel Approach to Interstitial Brachytherapy Planning in the
Treatment of Gynecological Malignancies: The RWJ Experience
Venkat Narra, PhD1,2. 1Radiation Oncology, Rutgers Cancer
Institute of New Jersey, New Brunswick, NJ, 2Radiation
Oncology, Robert Wood Johnson University Hospital, New
Brunswick, NJ.PD60
Radiopaque Polymer Hydrogel Used as a Fiducial Marker in
Gynecologic Brachytherapy
Ryan J. Bair, MD.1,2. 1Radiation Oncology, University of
Chicago, Chicago, IL, 2Radiology, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA.PD61
Dosimetric Comparison of Heterogeniety Versus Nonheterogeneity
Corrected Dose Calculations in Vaginal Brachytherapy. The Impact
of Air Gaps
Maria Bellon, Masters in Medical Physics, Radiation Oncology,
Henry Ford Hospital, Detroit, MI.PD62
Clinical Outcomes for 3-Dimensional High-Dose-Rate Vaginal
Brachytherapy Using an Intravaginal Multichannel Cylinder:
Improving Dosimetry to Decrease Toxicity for Primary and
Recurrent Vaginal Cancers
John A. Vargo, MD. Radiation Oncology, University of
Pittsburgh Cancer Institute, Pittsburgh, PA.PD63
Image-Based High-Dose-Rate Brachytherapy Salvage for Vaginal
Recurrences of Endometrial Cancer: The Interplay of PORTEC 1
Risk Stratification
John A. Vargo, MD. Radiation Oncology, University of
Pittsburgh Cancer Institute, Pittsburgh, PA.PD64
Dosimetric Comparison of Simultaneous Integrated Boost Regimen
Using Flexible Inflatable Multi-Channel Versus Single Channel
Vaginal Applicator in the Management of Gynecologic Cancer
Samuel M. Shin, MD. Radiation Oncology, NYU Langone
Medical Center, New York, NY.PD65
Sexual Function in Surviving Women with Endometrial Carcinoma
after Hysterectomy and Adjuvant Radiation Therapy
Mohamed A. Elshaikh, MD. Radiation Oncology, Henry Ford
Hospital, Detroit, MI.PD66
Treatment Planning Optimization for High-Dose-Rate Vaginal
Brachytherapy Using a Multichannel Applicator
Yasir A. Bahadur, Prof, King Abdulaziz University Hospital,
Jeddah, Saudi Arabia.PD67
Transvaginal Ultrasound-Guided Transperineal Interstitial
Brachytherapy for Vaginal Tumors: A Fixed Template Technique
Jim N. Rose, MD. Radiation Oncology, British Columbia Cancer
Agency, Kelowna, BC, Canada.PD68
Vaginal Brachytherapy as the Sole Radiotherapeutic Treatment for
Stage I Carcinosarcoma of the Uterus
Lindsay Brown, MD. Radiation Oncology, Mayo Clinic,
Rochester, MN.PD69
Vaginal Cuff Brachytherapy after External Beam Radiation is not
Associated with a Dose-Related Increase in Late Toxicities
Devarati Mitra, PhD. Harvard Medical School, Cambridge, MA.PD70
Adjuvant Vaginal Cuff Brachytherapy for High-Risk, Early Stage
Endometrial Cancer: A Single-Institution Experience
Harriet Eldredge-Hindy, MD. Radiation Oncology, Thomas
Jefferson University Hospital, Philadelphia, PA.PD71
Is There a Subset of Patients with Recurrent Cancer in the Vagina
That Can Be Treated with Vaginal Brachytherapy Using Graphic
Optimization Who Are Not a Candidate for Syed Implant?
Deepinder P. Singh, MD. Radiation Oncology, University Of
Rochester, Rochester, NY.
POSTER DISCUSSION: BREAST
Saturday, April 5, 2014
9:30 AM - 10:30 AM
PD72
Targeted Brachytherapy Boost Using Innovative Targeting
Linda Ann Smith, MD. Breast Surgeon, Heights General Medical
Center, Comprehensive Breast Care, Albuquerque, NM.PD73
A Novel CT-Based Permanent Breast Implant Technique Using
External Guiding Tools and Markers
Yen Pham, MSc. Medical Physics, BC Cancer Agency -
Vancouver Island Centre, Victoria, BC, Canada.PD74
Deformable Image Registration for Defining the Postoperative
Seroma in PBSI
Michelle Hilts, PhD. BC Cancer Agency - Southern Interior,
Kelowna, BC, Canada.
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Minimally Invasive Intraoperative Multicatheter Breast Implant for
Perioperative High-Dose-Rate Brachytherapy in Early Breast
Cancer Treated with Conservative Surgery
Mauricio Cambeiro, MD. Radiation Oncology, Clinica
Universidad de Navarra, Pamplona, Spain.PD76
Factors Influencing Eligibility for Breast Boost Using Non-Invasive
Image-Guided Breast Brachytherapy (NIBB)
Jaroslaw T. Hepel, MD1,2. 1Radiation Oncology, Rhode Island
Hospital, Brown University, Provicence, RI, 2Tufts Medical
Center, Tufts University, Boston, MA.PD77
Dosimetric Comparison and Early Clinical Outcomes of Interstitial
Versus Strut Assisted Volume Implants (SAVI) for Accelerated
Partial Breast Irradiation
Mitchell Kamrava, MD. Radiation Onocology, University of
California Los Angeles, Los Angeles, CA.PD78
Clinical Experience with a Miniature Accelerated Partial Breast
Irradiation Device: A 5-Year Single Institution Comprehensive
Study
S¸erban Morcovescu, MS, DABR. Radiation Oncology, Texas
Oncology Denton, Denton, TX.PD79
Feasibility of Permanent Breast Seed Implants in British Columbia:
Preliminary Dosimetric and Safety Results
Yen Pham, MSc. Medical Physics, BC Cancer Agency -
Vancouver Island Centre, Victoria, BC, Canada.PD80
Increasing Efficiency in Multi-Catheter High-Dose-Rate
Brachytherapy for Breast Cancer
Deidre Batchelar, PhD. BC Cancer Agency - Southern Interior,
Kelowna, BC, Canada.PD81
Accelerated Partial Breast Irradiation with Multicatheter High-
Dose-Rate Brachytherapy: Feasibility and Results in a Private
Practice Cohort
Richard Benjamin Young, BA. Radiation Oncology, Frank C.
Love Cancer Institute, Oklahoma City, OK.PD82
Simulation and Intraoperative Checks for Improved
Standardization and Reproducibility of Partial Breast Seed Implant
Technique
Deidre Batchelar, PhD. BCCA- SAH Centre for the Southern
Interior, Kelowna, BC, Canada.PD83
Chest Wall Scar Boost Using High-Dose-Rate Freiberg Flap and
Comparison to Electron Field
Ashraf Youssef, MD, MBA, Radiation Oncology, Cooper
University Hospital, Camden, NJ.BREAST POSTERS
Wednesday - Friday
PO01
Withdrawn
PO02
Assessment of Dosimetric Changes and Adaptive Replanning for
Intraoperatively Placed Brachytherapy Applicators During
Accelerated Partial Breast Irradiation (APBI)
Brad J. Stish, MD. Radiation Oncology, Mayo Clinic, Rochester,
MN.PO03
Withdrawn
PO04
Withdrawn
PO05
Withdrawn
PO06
A Single Site Prospective, Non-Randomized Study of Accelerated
Partial Breast Irradiation Brachytherapy for Early Stage Breast
Cancer Treatment to Evaluate Local Tumor Control, Cosmetic
Outcome, and Toxicities
Shalin Shah, BS. Saint Vincent’s Medical Center, Bridgeport, CT.
PO07
Assessment of Motion Effects on the Dosimetry of Breast Irradiation
Using SAVI Applicator
Michael Derr, MS. McLaren-Macomb, Mt. Clemens, MI.GYNECOLOGY POSTERS
Wednesday - Friday
PO08
A Retrospective Analysis of Primary Radiation Therapy for
Medically Inoperable Stage I-II Endometrial Cancer
Adrianna L. Henson, PhD1,2. 1School of Medicine, University of
Louisville, Louisville, KY, 2Radiation Oncology, University of
North Carolina at Chapel Hill, Chapel Hill, NC.PO09
The Effect of Tandem Angle and Tandem Length on Normal
Structure Dose in Cervical Cancer Patients Treated with Tandem
and Ring Applicators
Christopher Busselberg, MS. Radiation Oncology, Duke
University Medical Center, Durham, NC.
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A Method to Estimate the Spatial Distribution of Bladder Hot Spots
in Image-Guided Intracavitary Brachytherapy of Cervical Cancer
Roja Zakariaee, MSc. Physics, University of British Columbia,
Vancouver, BC, Canada.PO11
MRI Versus CT Contouring of the High-Risk CTV for HDR
Intracavitary Brachytherapy of Cervical Cancer Patients: Love’s
Labor Lost in the Dose?
Brian Hrycushko, PhD. Radiation Oncology, University of Texas
Southwestern Medical Center, Dallas, TX.PO12
Clinical Effect after Different Dose Treatment Planning
Brachytherapy Cancer of the Cervix
Vladimir G. Turkevich, MD. Radiation Oncology and Radiology,
N.N. Petrov Research Institute of Oncology, Saint-Petersburg,
Russian Federation.
PO13
Short-Term Clinical Outcome and Dosimetric Comparison of
Tandem and Ring vs Tandem and Ovoids Intracavitary Applicators
John K. Ma, MD, PhD. Radiation Oncology, University of
Mississippi, Jackson, MS.PO14
Clinical Outcomes of Vaginal Carcinoma Following Definitive
Radiotherapy, Chemotherapy, and HDR Brachytherapy
Addison B. Willett, JD, MBA1,2. 1Willis Knighton, Shreveport,
LA, 2LSU Health Shreveport, Shreveport, LA.PO15
Feasibility of Combined Intracavitary-Interstitial High-Dose-Rate
Brachytherapy with a Novel MR-Compatible Split-Ring Applicator
Sasan Partovi, MD. Radiology, UH Seidman Cancer Center,
University Hospitals Case Medical Center, Case Western
Reserve University, Cleveland, OH.PO16
Rectum and Bladder Dose from External Beam Radiotherapy and
High-Dose-Rate Brachytherapy in Cervix Uteri Cancer Patients:
From 2D Calculation to 3D Dose Optimization to Clinical Results
Mohamed E. El Sayed, MSc, PhD1,2. 1Oncology, Radiation
Oncology Section, King Faisal Specialist Hospital and Research
Center, Jeddah, Saudi Arabia; 2Radiation Oncology and Nuclear
Medicine, National Cancer Institute, Cairo, Saudi Arabia.PO17
Variations of the Rectum and Bladder Doses Relative to Point A in
High-Dose-Rate Brachytherapy Treatment of the Cervix Uteri
Cancer Patients
Mohamed E. El Sayed, PhD1,2. 1Oncology, Radiation Oncology
Section, King Faisal Specialist Hospital and Research Center,
Jeddah, Saudi Arabia, 2Radiation Oncology and Nuclear
Medicine, National Cancer Institute- Cairo University, Cairo,
Egypt.PO18
High-Dose-Rate Brachytherapy in Addition to External Beam
Radiotherapy with or without Concurrent Chemotherapy in Cervix
Uteri Cancer Patients: Clinical Results and Toxicity Profile
Mohamed E. El Sayed, PhD1,2. 1Oncology, Radiation Oncology
Section, King Faisal Specialist Hospital and Research Center,
Jeddah, Saudi Arabia; 2Radiation Oncology and Nuclear
Medicine, National Cancer Institute-Cairo University, Cairo,
Egypt.
PO19
Is Stereotactic Body Radiation Therapy a Feasible Alternative to
Brachytherapy for Definitive Treatment of Medically Inoperable
Early Stage Endometrial Cancer?
Ryan T. Jones, BA. Radiation Oncology, University of Virginia,
Charlottesville, VA.PO20
3D Printed Custom Applicator for High-Dose-Rate Intracavitary
Vaginal Cuff Brachytherapy
Rajni Sethi, MD. Radiation Oncology, UC San Francisco, San
Francisco, CA.PO21
A Custom-made Urethral Applicator for High-Dose-Rate
Brachytherapy in Advanced Vaginal Cancer
Kartik M. Mani, MD, PhD, Radiation Oncology, Montefiore
Medical Center, Bronx, NY.PHYSICS POSTERS
Wednesday - Friday
PO22
Effects of MRI Acquisition Parameters on the Susceptibility
Artifacts of Titanium Applicators for Cervix Cancer Brachytherapy
Jacqueline Esthappan, PhD. Washington University School of
Medicine, Saint Louis, MO.PO23
On the Influence of HDR Ir-192 Source Position Uncertainty on Dose
Variation within the Varian Ring Applicator
Yun Yang, PhD. Radiation Oncology, Duke University Medical
Center, Durham, NC.PO24
Masking Enhances Accuracy of Bladder Deformation in
Multifraction Adaptive Brachytherapy as a First Step toward
Composite Dose Estimation
Jennifer Barclay, BS. UT Southwestern, Dallas, TX.PO25
Effect of Dwell-Time Gradient and Optimization-point
Configuration on Dosimetry and Sensitivity to Dwell-position Error
in Vaginal Cuff Brachytherapy Plans
Iquan Usta, RT. Radiation Oncology, Dana-Farber Cancer
Institute/Brigham and Women’s Hospital, Boston, MA.
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Dose Distributions for an 125I Seed and the USC #9 Plaque with
Design Variations
Prakash Aryal, MS. Radiation Medicine, University of Kentucky,
Lexington, KY.
PO27
Brachyverifier: An Automated System for Plan Quality Assurance in
High-Dose-Rate Brachytherapy
Antonio L. Damato, PhD. Radiation Oncology, Dana Farber
Cancer Institute/Brigham and Women’s Hospital, Boston, MA.
PO28
Effect of Heterogeneity on Dose Deposited by a Flat HDR Surface
Applicator
Mandar S. Bhagwat, PhD1,2. 1Dana Farber Brigham and
Women’s Cancer Center, Boston, MA, 2Harvard Medical School,
Boston, MA.
PO29
Importance on the Development of a Clinic-Specific Source Path
Position Library while Commissioning Ring Applicators when
Compared to the Position of Applicator Markers and to the Ring
Source Path Position Library Model Currently in Use by Oncentra
Treatment Planning
Fabiola Vallejo, MSc, PhD, MCCPM. Service de Physique
Medicale, CICL, Centre Integre de Cancerologie de Laval,
Laval, QC, Canada.
PO30
Backscatter and Transmission through a Lead Shield Used in
Surface and Interstitial HDR Brachytherapy
Cristian Candela-Juan, MSc. Radioprotection, La Fe University
and Polytechnic Hospital, Valencia, Spain.
PO31
A Robust Quality Assurance Program for Determination of the Air
Kerma Strength and Source Characteristics of the Xoft Axxent
Electronic Brachytherapy Source
Sujatha Pai, MS, DABMP. Good Samaritan Hospital, Radion
Global, Inc, Cupertino, CA.PO32
HDR GYN: Tandem and Ring Planning Procedure for Special Cases
Ileana Iftimia, PhD. Radiation Oncology, Lahey Clinic,
Burlington, MA.PO33
Evaluate and Compare the Doses Differences between Line Source
and Point Source Calculation Methods for Episcleral Plaque
Brachytherapy
Vi Nhan Nguyen, MS. Radiation Oncology, The University of
Arizona, Tucson, AZ.PO34
Study of Dosimetric and Spatial Variations Due To Applicator
Positioning During Inter-fraction High-Dose-Rate Brachytherapy in
the Treatment of Carcinoma of Cervix - A 3D Dosimetric AnalysisManish K. Goyal, MS1,2. 1Texas Oncology, Fort Worth, TX,
2Biomedical Engineering, Shobhit University, Meerut, UP, India.PO35
Small Variations in Contouring Organs at Risk for Cervix HDR
Brachytherapy Result in Significant Impact on GEC-ESTRO 2cc
Doses
Jennifer Barclay, BS. UT Southwestern, Dallas, TX.PO36
The Importance of Motion Control in High-Dose-Rate
Brachytherapy Treatments
Silvia Pella, PhD1,2. 1Radiation Oncology, SFRO, Boca Raton,
FL, 2Physics, Florida Atlantic University, Boca Raton, FL.PO37
Dose Measurements for an Ir-192 Source Using Mosfets,
Radiochromic Films, TLDs and Heterogeneous Tissues
Gabriel P. Fonseca, MSc. Centro de Engenharia Nuclear,
Instituto de Pesquisas Energeticas e Nucleares, S~ao Paulo,
Brazil.PO38
Bladder and Rectal Dose Estimations on Digitized Radiographs for
Adjuvant Vaginal Brachytherapy after Hysterectomy
Winson Zhang, BS. Biomedical Engineering, University of Iowa,
Iowa City, IA.PO39
Skin HDR Using the Varian Catheter Flap: A Case Study
Ileana Iftimia, PhD. Radiation Oncology, Lahey Clinic,
Burlington, MA.PO40
A Comparison of Forward Planning vs. Inverse Planning Simulated
Annealing for Accelerated Partial Breast Irradiation Multi Channel
Catheter Brachytherapy
Meredith A. Semon, MS. Radiation Oncology, Monongahela
Valley Hospital, Monongahela, PA.PO41
Technological Solutions for the Transition to an Electronic Medical
Record System in a High-Dose-Rate Brachytherapy Practice
Antonio L. Damato, PhD. Radiation Oncology, Dana-Farber
Cancer Institute/Brigham and Women’s Hospital, Boston, MA.PO42
Customized Planning for Radioactive 125I Seeds Implant
Nan Zhao, MS. Radiation Oncology, Peking University Third
Hospital, Beijing, China.PO43
A Dwell Energy Density Distribution Index in Evaluation of the
High-Dose-Rate Accelerated Partial Breast Irradiation
S12 Listing of Presentations / Brachytherapy 13 (2014) S1eS14Kaile Li, PhD. Cancer Center, Associates in Medical Physics,
Hagerstown, MD.MISCELLANEOUS POSTERS
Wednesday - Friday
PO44
Initial Experience with Electronic Brachytherapy for Skin Cancer:
Clinical and Dosimetric Characteristics
Rakesh R. Patel, MD. The Targeted Radiation Institute @VMOC,
Pleasanton, CA.
PO45
Technical Description of a Successful Salvage Brachytherapy
Procedure for Recurrent Squamous Cell Carcinoma Isolated in the
Level II Neck
John Keith Hayes, MD, MS. Brachytherapy, GammaWest Cancer
Services, Salt Lake City, UT.
PO46
A New Attempt d Surgery Combined with Attachment of 125I
Seeds to the Tumor Bed for Treatment of Locally Advanced
Pancreatic Cancer
Gao Yang, Bachelor of Medicine. Department of Radiation
Oncology, BeiJing, China.
PO47
Management of Adenoid Cystic Carcinoma Metastatic to Lung with
CT-Fluoroscopic Guided Brachytherapy
Stephen Doggett, MD. Radiation Oncology, Mission Regional
Medical Center, Mission Viejo, CA.
PO48
Withdrawn
PO49
Novel Use of Negative-Pressure Wound Closure for Successful HDR
Brachytherapy Following Radical Resection of Recurrent
Pleomorphic Sarcoma without Immediate Reconstruction
Amit B. Shah, MD. Radiation Oncology, York Cancer Center,
Wellspan Health, York, PA.
PO50
The Anti-Tumor Effects of Iodine-125 Radioactive Seeds Radiation
in Nasopharyngeal Carcinoma
Li Jinna, Doctor. Cancer Center, Peking University Third
Hospital, Beijing, China.
PO51
The Results of Interstitial Permanent Implantation of 125-I Seeds for
Refractory Chest Wall Metastasis or Recurrence
Ping Jiang, MD. Radiation Oncology, Peking University Third
Hospital, Beijing, China.
PO52
Quantitative Analysis of Marker Based Treatment Setup
Uncertainty and its Correlation to Treatment Response for HDR
Endorectal Brachytherapy
Yi Le, PhD. Johns Hopkins University, Baltimore, MD.PO53
Radiation Exposure after Neurosurgical Resection and Permanent
Intraoperative Cesium-131 Radio-isotope Brachytherapy in Patients
with Brain Tumors
Menachem Z. Yondorf, BS. Radiation Oncology, Weill Cornell
Medical College, New York, NY.PO54
Dose Fidelity and Conformality for High-Dose-Rate Surface
Applicator Brachytherapy for Cutaneous Lymphoma Lesions of the
Hands and Feet
Phillip M. Devlin, MD. Brachytherapy, Harvard Medical School,
Boston, MA.PROSTATE POSTERS
Wednesday - Friday
PO55
Prostate Volume Before and After Neoadjuvant Cytoreductive
Androgen Suppression and Potential Predictors of Cytoreductive
Efficacy
Krishan R. Jethwa, BS. Radiation Oncology, Mayo Clinic,
Rochester, MN.PO56
Long Term Outcome Analysis of Permanent Prostate Brachytherapy
Using Patient Reported Outcomes: ACritical Self Assessment from a
Single Institution Experience
Peter J. Rossi, MD. Radiation Oncology, Emory University
School of Medicine and Winship Cancer Institute, Atlanta, GA.PO57
Evaluation of Prostate Volume and Shape Change after Permanent
Prostate Brachytherapy Using a Novel Deformable Registration
Method
Yi Le, PhD, Johns Hopkins University, Baltimore, MD.PO58
Robotic Manipulator Using Soft Pneumatic Air-muscles Actuators
for Needle Guidance in a Phantom Brachytherapy under TRUS
Visualization
Andre-Guy Martin, MD, MSc, FRCP(C)1,2. 1Radiation
Oncology, CHU de Quebec, Quebec, QC, Canada, 2Centre de
Recherche en Oncologie du CHUQ, Quebec, QC, Canada.PO59
Rectal Dose Vs. Rectal Separation: A Dosimetric Study from a Single
I-125, Cs-131 and Pd-103 Seed
Ravindra Yaparpalvi, MS. Radiation Oncology, Montefiore
Medical Center, Bronx, NY.PO60
5-Alpha-Reductase Inhibitors in Combination with Permanent Seed
Prostate Brachytherapy
Daniel Taussky, MD. Radiation Oncology, University of
Montreal, Montreal, QC, Canada.
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Salvage Low-Dose-Rate 125Iodine Partial Prostate Brachytherapy
after Dose-Escalated External Beam Radiotherapy
Lynn Chang, MD. Radiation Oncology, Fox Chase Cancer
Center, Philadelphia, PA.PO62
Toxicity Associated with High-Dose-Rate Monotherapy for Prostate
Cancer
Robyn Banerjee, MD. Oncology, University of Calgary, Calgary,
AB, Canada.PO63
Discrepancies of Catheter Reconstruction in Ultrasound Image
Guided Prostate High-Dose-Rate Brachytherapy and Their Effects
to Dosimetry
Amy Limbacher, B.S., R.T (T). Radiation Oncology, Beaumont
Health System, Royal Oak, MI.PO64
Clinical Evaluation of a Commercial Real-Time Dosimetry Platform
for Prostate Seed Implantation
Elisha T. Fredman, BS. Case Western Reserve University School
of Medicine, Cleveland, OH.PO65
Distinguishing Prostate-Specific Antigen Bounce from Biochemical
Failure after Low-Dose-Rate Prostate Brachytherapy
Cian Hackett, BSc. Oncology, University of Alberta, Edmonton,
AB, Canada.PO66
The Cancer of the Prostate Risk Assessment Score Predicts
Biochemical Recurrence in Intermediate-Risk Prostate Cancer
Treated with EBRT Dose Escalation or LDR Brachytherapy
Guila Delouya, MD. Radiation Oncology, University of
Montreal, Montreal, QC, Canada.PO67
Dosimetric Feasibility of MR-Based Ultra-Focal High-Dose-Rate
Brachytherapy for Prostate Cancer
Sang-June Park, PhD. Radiation Oncology, University of
California Los Angeles, Los Angeles, CA.PO68
Focal Salvage HDR Brachytherapy for Local Prostate Cancer
Recurrence after a Primary Radiation Therapy: Early Experience of
Prospective Study
Stephane Guerif, MD. Radiation Oncology, CHU, Poitiers,
France.PO69
Brachytherapy Treatment Planning for Prostate Cancer with the Use
of Computed Tomography-Based Planning Software in Patients afterTotal Primary Amputation of the Rectum and External Beam
Radiation Therapy Due to Rectal Cancer
Łukasz Kowalik, MSc. Brachytherapy, Podkarpacki Cancer
Center, Brzozow, Poland.PO70
A Prospective Cohort Analysis of Two Brachytherapy Techniques
for Low/Intermediate Risk Prostate Cancer
Laura D’Alimonte, MRT(T), MHSc. Odette Cancer Centre,
Sunnybrook Health Science Centre, Toronto, ON, Canada.
PO71
Intraoperative Prostate Volume Change During Permanent Low-
Dose-Rate I-125 Prostate Brachytherapy: Implications for Final
Implant Dosimetry
David E. Greene, MD, Radiation Oncology, UC Davis
Comprehensive Cancer Center, Sacramento, CA.
PO72
Definitive Multifraction High-Dose-Rate Monotherapy for Prostate
Cancer Is Associated with Minimal Short-Term Toxicity and
Improvement in Long-Term Urinary Function
David R. Raleigh, MD, PhD. Radiation Oncology, University of
California San Francisco, San Francisco, CA.PO73
Prostate Cancer Dose Escalation via Simultaneous Integrated
Brachytherapy Boost Delivered via Radioactive I125 vs. Pd103 Seeds
followed by External Beam Radiation Therapy
Waleed F. Mourad, M.D1,2. 1Radiation Oncology, Beth Israel
Medical Center, New York, NY; 2Radiation Oncology, Albert
Einstein College of Medicine, New York, NY.
PO74
Interstitial Prostate Brachytherapy Outcomes (1992-2002): Late
Urinary Function Following Molecular Image-Guided Therapy
Shree Agrawal, BS. Radiation Oncology, University Hospitals
Seidman Cancer Center, Cleveland, OH.PO75
Addressing Dose Volume Histogram Based Optimization Challenges
for Real-Time High-Dose-Rate Prostate Brachytherapy
Aaron Vandermeer, PhD. Medical Physics, Durham Regional
Cancer Centre, Oshawa, ON, Canada.PO76
Predictors of Acute Urinary Toxicity in Prostate Cancer Patients
Treated with a Combined Low-Dose-Rate Brachytherapy and
External Beam Radiotherapy
Lara Hathout, MD, FRCPC. Radiation Oncology, Memorial
Sloan Kettering Cancer Center, New York, NY.PO77
Comparison of A1-Blockers for Acute Urinary Symptoms after
Prostate Brachytherapy
Tadahiko Kikugawa, MD, PhD. Urology, Ehime University,
Toon, Japan.
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Is It Necessary to Perform Post-Implant Dosimetric Analysis in Low-
Dose-Rate Brachytherapy for Prostate Cancer? A Quality Assurance
Assessment
Talha Shaikh, MD, Fox Chase Cancer Center, Philadelphia, PA.PO79
What Does a PSA Bounce Look Like? A Numerical and Graphical
Description of the Bounce Phenomenon in 592 Patients Treated with
I-125 Prostate Brachytherapy
Daniel R. Zwahlen, MD, MBA. Radiation Oncology,
Kantonsspital Graubuenden, Chur, Switzerland.PO80
Interstitial Prostate Brachytherapy Outcomes (1992-2002): Sexual
Function Following Molecular Image-Guided Therapy
Shree Agrawal, BS. Radiation Oncology, University Hospitals
Seidman Cancer Center, Cleveland, OH.PO81
Combining Multi-Modality Imaging and Trans-Perineal Mapping
Biopsy to Guide the Focal Application of Low-Dose-Rate
Brachytherapy for Prostate Cancer: An Ethics Approved Pilot Study
S. Sara Mahdavi, PhD. BCCA - Vancouver Center, Vancouver,
BC, Canada.PO82
Developing Volume Based Catheter Placement Guidelines for Real-
Time High-Dose-Rate Prostate Brachytherapy
Aaron Vandermeer, PhD. Medical Physics, Durham Regional
Cancer Centre, Oshawa, ON, Canada.PO83
Dosimetric and Clinical Implications of Prostate Volume in Patients
Managed with Low-Dose-Rate Interstitial BrachytherapyRebekah Maymani, MD. Radiation Oncology, Oklahoma
University Health Sciences Center, Oklahoma City, OK.PO84
Smoking History as a Predictor of Secondary Malignancy Among
Prostate Brachytherapy Patients
Emily Steinberger, BA. Radiation Oncology, Memorial Sloan
Kettering Cancer Center, New York, NY.PO85
Comparison of Multiparametric MRI-Based and TRUS-Based
Preplans with Intraoperative Ultrasound-Based Planning for
Interstitial Prostate Seed Implantation
Elisha T. Fredman, BS. Case Western Reserve University School
of Medicine, Cleveland, OH.PO86
The Quadrella: A Novel Approach to Analyzing Optimal Outcomes
after Permanent Seed Prostate Brachytherapy
Audrey Tetreault-Laflamme, MD. Radiation Oncology,
University of Montreal, Montreal, QC, Canada.PO87
One and Done: Seed Implant Brachytherapy Alone for Gleason 7
Prostate Cancer
John M. Watkins, MD. Bismarck Cancer Center, Bismarck, ND.PO88
Customized Needle Guides for Inserting Non-Parallel Needle
Arrangements in Prostate HDR Brachytherapy: A Phantom Study
Timmy Siauw, PhD. Radiation Oncology, UCSF, San Francisco,
CA.PO89
Withdrawn
